Public Meeting on Fibromyalgia Patient-Focused Drug Development
Important Update, 12/10/2013 This meeting has been postponed due to the closing of the federal government, in anticipation of inclement weather. More information on a rescheduled date will be posted in the future.
Important Update, 12/10/2013
This meeting has been postponed due to the closing of the federal government, in anticipation of inclement weather. More information on a rescheduled date will be posted in the future.
On December 10, 2013, FDA is conducting a public meeting on Patient-Focused Drug Development for fibromyalgia. FDA is interested in obtaining patient input on the impact of fibromyalgia on daily life and patients’ views on currently available therapies to treat the condition.
This website will be updated as additional meeting information becomes available.
Date: December 10, 2013 Time: 1:00 p.m. to 5:00 p.m. Location: FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)
Registration will close on December 2, 2013.
Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders can provide their perspectives on the discussion questions through the public docket. The docket closes on February 10, 2014. To submit your comments, visit http://www.regulations.gov/#!documentDetail;D=FDA-2013-N-1041-0001.
Alternatively, you can fax or mail your comments. Fax comments to the Division of Dockets Management at 301-827-6870, or mail comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should include the docket number FDA-2013-N-1041.